File size: 73,651 Bytes
9754890
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.read_csv('../ClinicalTrialCSV/JRCT20241129Cancer.csv', index_col=0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>JRCT ID</th>\n",
       "      <th>Title</th>\n",
       "      <th>Target</th>\n",
       "      <th>研究・治験の目的</th>\n",
       "      <th>試験の種類</th>\n",
       "      <th>無作為化</th>\n",
       "      <th>盲検化</th>\n",
       "      <th>対照</th>\n",
       "      <th>割付け</th>\n",
       "      <th>研究目的</th>\n",
       "      <th>...</th>\n",
       "      <th>purpose</th>\n",
       "      <th>Inclusion Criteria</th>\n",
       "      <th>Exclusion Criteria</th>\n",
       "      <th>Age Minimum</th>\n",
       "      <th>Age Maximum</th>\n",
       "      <th>Gender</th>\n",
       "      <th>Discontinuation Criteria</th>\n",
       "      <th>Keyword</th>\n",
       "      <th>Intervention(s)</th>\n",
       "      <th>Phase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>jRCT1030240513</td>\n",
       "      <td>進行がん患者に対する可聴領域外のハイレゾ自然音源が与える生体情報や癒しの変化を評価する\\n探...</td>\n",
       "      <td>がん</td>\n",
       "      <td>進行がん患者を対象に、可聴領域外のハイレゾ自然音源を介入とした音楽療法が、無音と比較して、疲...</td>\n",
       "      <td>介入研究</td>\n",
       "      <td>無作為化比較</td>\n",
       "      <td>単盲検</td>\n",
       "      <td>プラセボ対照</td>\n",
       "      <td>並行群間比較</td>\n",
       "      <td>緩和</td>\n",
       "      <td>...</td>\n",
       "      <td>supportive care</td>\n",
       "      <td>Eligible participants must meet the following ...</td>\n",
       "      <td>Exclusion criteria apply if any of the followi...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cancer,</td>\n",
       "      <td>Participants will be exposed to either sounds ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>jRCT1032240511</td>\n",
       "      <td>進行がん患者の痛みに対する交番磁界治療器の至適な治療時間の条件に関する多施設共同研究</td>\n",
       "      <td>がん患者の疼痛</td>\n",
       "      <td>交番磁界治療器を用いた自宅での疼痛治療について、進行がん患者が治療の継続が可能と考える治療時...</td>\n",
       "      <td>介入研究</td>\n",
       "      <td>単一群</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>その他</td>\n",
       "      <td>...</td>\n",
       "      <td>other</td>\n",
       "      <td>1. Age 18 years or older on the day of consent...</td>\n",
       "      <td>1. There is a skin disorder in the painful are...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Four pads of the alternating magnetic field th...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>jRCT1032240506</td>\n",
       "      <td>卵巣腫瘍手術での術中低圧換気介入による術中出血量に及ぼす影響:ランダム化比較試験</td>\n",
       "      <td>卵巣がん</td>\n",
       "      <td>卵巣悪性腫瘍手術は高侵襲な手術であり輸血率の高い手術である。一方で輸血により癌の予後が悪化す...</td>\n",
       "      <td>介入研究</td>\n",
       "      <td>無作為化比較</td>\n",
       "      <td>単盲検</td>\n",
       "      <td>実薬(治療)対照</td>\n",
       "      <td>並行群間比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>Patients undergoing ovarian cancer surgery at ...</td>\n",
       "      <td>1.Minors\\n\\r\\n2.Emergency surgery\\n\\r\\n3.Patie...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>100age old not</td>\n",
       "      <td>Female</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Low-pressure ventilation and low venous pressu...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>jRCT2041240130</td>\n",
       "      <td>中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...</td>\n",
       "      <td>肺がん</td>\n",
       "      <td>全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>無作為化比較</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>無治療対照/標準治療対照</td>\n",
       "      <td>並行群間比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>(1) Patients scheduled to undergo anatomical l...</td>\n",
       "      <td>(1) Patients with a history of allergy to the ...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Treatment group\\n\\r\\nAdminister GRA 1mg intrav...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>jRCT2031240500</td>\n",
       "      <td>ミスマッチ修復機能欠損(dMMR)又は高頻度マイクロサテライト不安定性(MSI-H)を有する...</td>\n",
       "      <td>ミスマッチ修復機能欠損(dMMR)又は高頻度マイクロサテライト不安定性(MSI-H)を有する...</td>\n",
       "      <td>固形がんは、体のさまざまな部位に発生する異常な組織の塊である。本治験は、特定の遺伝的特徴を持...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>単一群</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>Parts 1, 2, and 3 inclusion criteria: \\n\\r\\n-H...</td>\n",
       "      <td>Parts 1, 2, and 3 exclusion criteria:\\n\\r\\n-Ha...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Drug: GSK4418959\\n\\r\\nDrug:PD-1 inhibitor</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>282</th>\n",
       "      <td>jRCT2080223823</td>\n",
       "      <td>固形がん患者を対象としたE7130 の臨床第1相試験</td>\n",
       "      <td>Part1:固形がん\\nPart2:頭頸部がん,尿路上皮がん</td>\n",
       "      <td>NaN</td>\n",
       "      <td>介入研究</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>&lt;p&gt;Both&lt;/p&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>investigational material(s)&lt;br&gt;\\nGeneric name ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>283</th>\n",
       "      <td>jRCT1090220266</td>\n",
       "      <td>肺がん手術患者に対する運動療法とBCAA摂取の併用効果の検討</td>\n",
       "      <td>肺がん</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>実薬(治療)対照</td>\n",
       "      <td>なし</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Age Month Week Day Hour</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intervention type:BEHAVIOUR\\n\\nName of interve...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>284</th>\n",
       "      <td>jRCT1091220254</td>\n",
       "      <td>肺動静脈分離3D-CT angiographyにおけるヨード造影剤量低減の検討</td>\n",
       "      <td>肺がん</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>単盲検</td>\n",
       "      <td>用量比較</td>\n",
       "      <td>あり</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intervention type:DRUG\\n\\nName of intervention...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>285</th>\n",
       "      <td>jRCT1090220224</td>\n",
       "      <td>体幹部神経ブロック後のレボブピバカインの血中濃度の変化</td>\n",
       "      <td>下腹部消化器がん</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>無対照</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>20Age Month Week Day Hour over</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intervention type:\\n\\nName of intervention:\\n\\...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>286</th>\n",
       "      <td>jRCT1091220221</td>\n",
       "      <td>ヨード造影剤と生理食塩水の混合溶液を用いたtest injectionによる混合割合と造影効...</td>\n",
       "      <td>肺がん</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>無対照</td>\n",
       "      <td>なし</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intervention type:DRUG\\n\\nName of intervention...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>287 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            JRCT ID                                              Title  \\\n",
       "0    jRCT1030240513  進行がん患者に対する可聴領域外のハイレゾ自然音源が与える生体情報や癒しの変化を評価する\\n探...   \n",
       "1    jRCT1032240511         進行がん患者の痛みに対する交番磁界治療器の至適な治療時間の条件に関する多施設共同研究   \n",
       "2    jRCT1032240506           卵巣腫瘍手術での術中低圧換気介入による術中出血量に及ぼす影響:ランダム化比較試験   \n",
       "3    jRCT2041240130  中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...   \n",
       "4    jRCT2031240500  ミスマッチ修復機能欠損(dMMR)又は高頻度マイクロサテライト不安定性(MSI-H)を有する...   \n",
       "..              ...                                                ...   \n",
       "282  jRCT2080223823                         固形がん患者を対象としたE7130 の臨床第1相試験   \n",
       "283  jRCT1090220266                     肺がん手術患者に対する運動療法とBCAA摂取の併用効果の検討   \n",
       "284  jRCT1091220254            肺動静脈分離3D-CT angiographyにおけるヨード造影剤量低減の検討   \n",
       "285  jRCT1090220224                       体幹部神経ブロック後のレボブピバカインの血中濃度の変化    \n",
       "286  jRCT1091220221  ヨード造影剤と生理食塩水の混合溶液を用いたtest injectionによる混合割合と造影効...   \n",
       "\n",
       "                                                Target  \\\n",
       "0                                                   がん   \n",
       "1                                              がん患者の疼痛   \n",
       "2                                                 卵巣がん   \n",
       "3                                                  肺がん   \n",
       "4    ミスマッチ修復機能欠損(dMMR)又は高頻度マイクロサテライト不安定性(MSI-H)を有する...   \n",
       "..                                                 ...   \n",
       "282                     Part1:固形がん\\nPart2:頭頸部がん,尿路上皮がん   \n",
       "283                                                肺がん   \n",
       "284                                                肺がん   \n",
       "285                                          下腹部消化器がん    \n",
       "286                                                肺がん   \n",
       "\n",
       "                                              研究・治験の目的 試験の種類    無作為化  盲検化  \\\n",
       "0    進行がん患者を対象に、可聴領域外のハイレゾ自然音源を介入とした音楽療法が、無音と比較して、疲...  介入研究  無作為化比較  単盲検   \n",
       "1    交番磁界治療器を用いた自宅での疼痛治療について、進行がん患者が治療の継続が可能と考える治療時...  介入研究     単一群  非盲検   \n",
       "2    卵巣悪性腫瘍手術は高侵襲な手術であり輸血率の高い手術である。一方で輸血により癌の予後が悪化す...  介入研究  無作為化比較  単盲検   \n",
       "3    全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...   NaN  無作為化比較  非盲検   \n",
       "4    固形がんは、体のさまざまな部位に発生する異常な組織の塊である。本治験は、特定の遺伝的特徴を持...   NaN     単一群  非盲検   \n",
       "..                                                 ...   ...     ...  ...   \n",
       "282                                                NaN  介入研究     NaN  NaN   \n",
       "283                                                NaN   NaN     NaN  非盲検   \n",
       "284                                                NaN   NaN     NaN  単盲検   \n",
       "285                                                NaN   NaN     NaN  非盲検   \n",
       "286                                                NaN   NaN     NaN  非盲検   \n",
       "\n",
       "               対照     割付け 研究目的  ...            purpose  \\\n",
       "0          プラセボ対照  並行群間比較   緩和  ...    supportive care   \n",
       "1             非対照    単群比較  その他  ...              other   \n",
       "2        実薬(治療)対照  並行群間比較   治療  ...  treatment purpose   \n",
       "3    無治療対照/標準治療対照  並行群間比較   治療  ...  treatment purpose   \n",
       "4             非対照    単群比較   治療  ...  treatment purpose   \n",
       "..            ...     ...  ...  ...                ...   \n",
       "282           NaN     NaN  NaN  ...                NaN   \n",
       "283      実薬(治療)対照      なし  NaN  ...                NaN   \n",
       "284          用量比較      あり  NaN  ...                NaN   \n",
       "285           無対照     NaN  NaN  ...                NaN   \n",
       "286           無対照      なし  NaN  ...                NaN   \n",
       "\n",
       "                                    Inclusion Criteria  \\\n",
       "0    Eligible participants must meet the following ...   \n",
       "1    1. Age 18 years or older on the day of consent...   \n",
       "2    Patients undergoing ovarian cancer surgery at ...   \n",
       "3    (1) Patients scheduled to undergo anatomical l...   \n",
       "4    Parts 1, 2, and 3 inclusion criteria: \\n\\r\\n-H...   \n",
       "..                                                 ...   \n",
       "282                                                NaN   \n",
       "283                                                NaN   \n",
       "284                                                NaN   \n",
       "285                                                NaN   \n",
       "286                                                NaN   \n",
       "\n",
       "                                    Exclusion Criteria  \\\n",
       "0    Exclusion criteria apply if any of the followi...   \n",
       "1    1. There is a skin disorder in the painful are...   \n",
       "2    1.Minors\\n\\r\\n2.Emergency surgery\\n\\r\\n3.Patie...   \n",
       "3    (1) Patients with a history of allergy to the ...   \n",
       "4    Parts 1, 2, and 3 exclusion criteria:\\n\\r\\n-Ha...   \n",
       "..                                                 ...   \n",
       "282                                                NaN   \n",
       "283                                                NaN   \n",
       "284                                                NaN   \n",
       "285                                                NaN   \n",
       "286                                                NaN   \n",
       "\n",
       "                          Age Minimum                       Age Maximum  \\\n",
       "0                      18age old over                          No limit   \n",
       "1                      18age old over                          No limit   \n",
       "2                      18age old over                    100age old not   \n",
       "3                      18age old over                          No limit   \n",
       "4                      18age old over                          No limit   \n",
       "..                                ...                               ...   \n",
       "282                               NaN                               NaN   \n",
       "283           Age Month Week Day Hour  Age Month Week Day Hour No limit   \n",
       "284  Age Month Week Day Hour No limit  Age Month Week Day Hour No limit   \n",
       "285    20Age Month Week Day Hour over  Age Month Week Day Hour No limit   \n",
       "286  Age Month Week Day Hour No limit  Age Month Week Day Hour No limit   \n",
       "\n",
       "          Gender Discontinuation Criteria  Keyword  \\\n",
       "0            NaN                      NaN  cancer,   \n",
       "1           Both                      NaN      NaN   \n",
       "2         Female                      NaN      NaN   \n",
       "3           Both                      NaN      NaN   \n",
       "4           Both                      NaN      NaN   \n",
       "..           ...                      ...      ...   \n",
       "282  <p>Both</p>                      NaN      NaN   \n",
       "283         Both                      NaN      NaN   \n",
       "284         Both                      NaN      NaN   \n",
       "285         Both                      NaN      NaN   \n",
       "286         Both                      NaN      NaN   \n",
       "\n",
       "                                       Intervention(s) Phase  \n",
       "0    Participants will be exposed to either sounds ...   NaN  \n",
       "1    Four pads of the alternating magnetic field th...   NaN  \n",
       "2    Low-pressure ventilation and low venous pressu...   NaN  \n",
       "3    Treatment group\\n\\r\\nAdminister GRA 1mg intrav...   NaN  \n",
       "4            Drug: GSK4418959\\n\\r\\nDrug:PD-1 inhibitor   NaN  \n",
       "..                                                 ...   ...  \n",
       "282  investigational material(s)<br>\\nGeneric name ...   NaN  \n",
       "283  Intervention type:BEHAVIOUR\\n\\nName of interve...   NaN  \n",
       "284  Intervention type:DRUG\\n\\nName of intervention...   NaN  \n",
       "285  Intervention type:\\n\\nName of intervention:\\n\\...   NaN  \n",
       "286  Intervention type:DRUG\\n\\nName of intervention...   NaN  \n",
       "\n",
       "[287 rows x 35 columns]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>JRCT ID</th>\n",
       "      <th>Title</th>\n",
       "      <th>Target</th>\n",
       "      <th>研究・治験の目的</th>\n",
       "      <th>試験の種類</th>\n",
       "      <th>無作為化</th>\n",
       "      <th>盲検化</th>\n",
       "      <th>対照</th>\n",
       "      <th>割付け</th>\n",
       "      <th>研究目的</th>\n",
       "      <th>...</th>\n",
       "      <th>purpose</th>\n",
       "      <th>Inclusion Criteria</th>\n",
       "      <th>Exclusion Criteria</th>\n",
       "      <th>Age Minimum</th>\n",
       "      <th>Age Maximum</th>\n",
       "      <th>Gender</th>\n",
       "      <th>Discontinuation Criteria</th>\n",
       "      <th>Keyword</th>\n",
       "      <th>Intervention(s)</th>\n",
       "      <th>Phase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>jRCT2041240130</td>\n",
       "      <td>中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...</td>\n",
       "      <td>肺がん</td>\n",
       "      <td>全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>無作為化比較</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>無治療対照/標準治療対照</td>\n",
       "      <td>並行群間比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>(1) Patients scheduled to undergo anatomical l...</td>\n",
       "      <td>(1) Patients with a history of allergy to the ...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Treatment group\\n\\r\\nAdminister GRA 1mg intrav...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>jRCT2031240500</td>\n",
       "      <td>ミスマッチ修復機能欠損(dMMR)又は高頻度マイクロサテライト不安定性(MSI-H)を有する...</td>\n",
       "      <td>ミスマッチ修復機能欠損(dMMR)又は高頻度マイクロサテライト不安定性(MSI-H)を有する...</td>\n",
       "      <td>固形がんは、体のさまざまな部位に発生する異常な組織の塊である。本治験は、特定の遺伝的特徴を持...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>単一群</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>Parts 1, 2, and 3 inclusion criteria: \\n\\r\\n-H...</td>\n",
       "      <td>Parts 1, 2, and 3 exclusion criteria:\\n\\r\\n-Ha...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Drug: GSK4418959\\n\\r\\nDrug:PD-1 inhibitor</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>jRCT2031240448</td>\n",
       "      <td>切除不能皮膚血管肉腫に対するペムブロリズマブ+レンバチニブ併用療法の第II相医師主導治験</td>\n",
       "      <td>切除不能皮膚血管肉腫</td>\n",
       "      <td>切除不能皮膚血管肉腫に対するペムブロリズマブ+レンバチニブ併用療法の有効性を検証し、有効性と...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>単一群</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>1)\\tHistologically diagnosed with cutaneous an...</td>\n",
       "      <td>1)\\tPatients previously treated with anti-PD-1...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>85age old under</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cutaneous angiosarcoma, angiosarcoma</td>\n",
       "      <td>Each course is set at 21 days. Pembrolizumab 2...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>jRCT2031240404</td>\n",
       "      <td>転移性HR+/HER2-乳がん及びその他の進行性固形がん患者を対象にCDK4阻害剤BGB-4...</td>\n",
       "      <td>・進行性固形腫瘍・進行性乳がん・転移性乳がん・ホルモン受容体陽性乳がん・ホルモン受容体陽性乳...</td>\n",
       "      <td>サイクリン依存性キナーゼ 4 (CDK4) 阻害剤である BGB-43395 が、ホルモン受...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>非無作為化比較</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>用量比較</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>-Phase 1a (Dose Escalation) and 1b (Dose Expan...</td>\n",
       "      <td>-Prior therapy selectively targeting CDK4 (pri...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-Drug: BGB-43395\\n\\r\\nPlanned doses administer...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>jRCT2031240381</td>\n",
       "      <td>進行固形がん患者を対象としたGSK5764227の安全性、忍容性、薬物動態、及び有効性を評価...</td>\n",
       "      <td>進行固形がん</td>\n",
       "      <td>GSK5764227の安全性、忍容性、薬物動態、及び有効性を評価する。評価する。また、GSK...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>非無作為化比較</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>-Male or female participants at least 18 years...</td>\n",
       "      <td>-Has ongoing adverse reaction(s) from prior th...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Drug: GSK5764227\\n\\r\\nGSK5764227 will be admin...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>238</th>\n",
       "      <td>jRCT2033200278</td>\n",
       "      <td>MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効...</td>\n",
       "      <td>多発性骨髄腫</td>\n",
       "      <td>【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体( MMG49)抗原陽性の再発・難治性のM...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>単一群</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>-Patients aged between 20 and 80 (75 for the p...</td>\n",
       "      <td>-Patients who are scheduled to receive high-do...</td>\n",
       "      <td>20age old over</td>\n",
       "      <td>80age old under</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>OPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>240</th>\n",
       "      <td>jRCT2051200105</td>\n",
       "      <td>標準化学療法に不応・不耐かつ外科的切除不能膵がん患者を対\\n象とした、 R-OKY-034F...</td>\n",
       "      <td>膵臓がん</td>\n",
       "      <td>標準化学療法に不応・不耐かつ外科的切除不能膵がん患者に対して、R-OKY-034Fを1日1回...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>単一群</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>1. Patients who are 20 years old or above at t...</td>\n",
       "      <td>1. Patients with active duplicate cancer\\n\\r\\n...</td>\n",
       "      <td>20age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Once a day for orally\\n\\r\\n1mg/kg, 2.5mg/kg, 5...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>242</th>\n",
       "      <td>jRCT2071200060</td>\n",
       "      <td>1 種類以上の全身療法を含む 2種類以上の治療で失敗、あるいは治療中または治療後に病勢進行が...</td>\n",
       "      <td>頭頸部扁平上皮がん</td>\n",
       "      <td>1種類以上の全身療法を含む2種類以上の治療で失敗、あるいは治療中また は治療後に病勢進行した...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>無作為化比較</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>実薬(治療)対照</td>\n",
       "      <td>並行群間比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>Patients must meet the following criteria to b...</td>\n",
       "      <td>Patients with any of the following will be exc...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ASP-1929 640mg/m^2 intravenous infusion by dri...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>257</th>\n",
       "      <td>jRCT2033190086</td>\n",
       "      <td>悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス1型の第...</td>\n",
       "      <td>悪性黒色腫</td>\n",
       "      <td>第Ⅰ相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>単一群</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>(Phase 1)\\n\\r\\n1) Histologically confirmed mal...</td>\n",
       "      <td>(Phase 1 and 2)\\n\\r\\n1) Patients who have brai...</td>\n",
       "      <td>20age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>malignamt  melanoma, advanced stage</td>\n",
       "      <td>Test drug (T-hIL12) will be administered into ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>261</th>\n",
       "      <td>jRCT2051190009</td>\n",
       "      <td>進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ(抗PD-1抗体...</td>\n",
       "      <td>進行性悪性黒色腫</td>\n",
       "      <td>抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>非無作為化比較</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>Inclusion criteria \\n\\r\\nPatients meeting all ...</td>\n",
       "      <td>Exclusion criteria\\n\\r\\nPatients meeting any o...</td>\n",
       "      <td>20age old over</td>\n",
       "      <td>86age old not</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>advanced melanoma</td>\n",
       "      <td>combination therapy of intracutaneous GEN0101 ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>124 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            JRCT ID                                              Title  \\\n",
       "3    jRCT2041240130  中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...   \n",
       "4    jRCT2031240500  ミスマッチ修復機能欠損(dMMR)又は高頻度マイクロサテライト不安定性(MSI-H)を有する...   \n",
       "9    jRCT2031240448       切除不能皮膚血管肉腫に対するペムブロリズマブ+レンバチニブ併用療法の第II相医師主導治験   \n",
       "12   jRCT2031240404  転移性HR+/HER2-乳がん及びその他の進行性固形がん患者を対象にCDK4阻害剤BGB-4...   \n",
       "13   jRCT2031240381  進行固形がん患者を対象としたGSK5764227の安全性、忍容性、薬物動態、及び有効性を評価...   \n",
       "..              ...                                                ...   \n",
       "238  jRCT2033200278  MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効...   \n",
       "240  jRCT2051200105  標準化学療法に不応・不耐かつ外科的切除不能膵がん患者を対\\n象とした、 R-OKY-034F...   \n",
       "242  jRCT2071200060  1 種類以上の全身療法を含む 2種類以上の治療で失敗、あるいは治療中または治療後に病勢進行が...   \n",
       "257  jRCT2033190086  悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス1型の第...   \n",
       "261  jRCT2051190009  進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ(抗PD-1抗体...   \n",
       "\n",
       "                                                Target  \\\n",
       "3                                                  肺がん   \n",
       "4    ミスマッチ修復機能欠損(dMMR)又は高頻度マイクロサテライト不安定性(MSI-H)を有する...   \n",
       "9                                           切除不能皮膚血管肉腫   \n",
       "12   ・進行性固形腫瘍・進行性乳がん・転移性乳がん・ホルモン受容体陽性乳がん・ホルモン受容体陽性乳...   \n",
       "13                                              進行固形がん   \n",
       "..                                                 ...   \n",
       "238                                             多発性骨髄腫   \n",
       "240                                               膵臓がん   \n",
       "242                                          頭頸部扁平上皮がん   \n",
       "257                                              悪性黒色腫   \n",
       "261                                           進行性悪性黒色腫   \n",
       "\n",
       "                                              研究・治験の目的 試験の種類     無作為化  盲検化  \\\n",
       "3    全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...   NaN   無作為化比較  非盲検   \n",
       "4    固形がんは、体のさまざまな部位に発生する異常な組織の塊である。本治験は、特定の遺伝的特徴を持...   NaN      単一群  非盲検   \n",
       "9    切除不能皮膚血管肉腫に対するペムブロリズマブ+レンバチニブ併用療法の有効性を検証し、有効性と...   NaN      単一群  非盲検   \n",
       "12   サイクリン依存性キナーゼ 4 (CDK4) 阻害剤である BGB-43395 が、ホルモン受...   NaN  非無作為化比較  非盲検   \n",
       "13   GSK5764227の安全性、忍容性、薬物動態、及び有効性を評価する。評価する。また、GSK...   NaN  非無作為化比較  非盲検   \n",
       "..                                                 ...   ...      ...  ...   \n",
       "238  【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体( MMG49)抗原陽性の再発・難治性のM...   NaN      単一群  非盲検   \n",
       "240  標準化学療法に不応・不耐かつ外科的切除不能膵がん患者に対して、R-OKY-034Fを1日1回...   NaN      単一群  非盲検   \n",
       "242  1種類以上の全身療法を含む2種類以上の治療で失敗、あるいは治療中また は治療後に病勢進行した...   NaN   無作為化比較  非盲検   \n",
       "257  第Ⅰ相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...   NaN      単一群  非盲検   \n",
       "261  抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...   NaN  非無作為化比較  非盲検   \n",
       "\n",
       "               対照     割付け 研究目的  ...            purpose  \\\n",
       "3    無治療対照/標準治療対照  並行群間比較   治療  ...  treatment purpose   \n",
       "4             非対照    単群比較   治療  ...  treatment purpose   \n",
       "9             非対照    単群比較   治療  ...  treatment purpose   \n",
       "12           用量比較    単群比較   治療  ...  treatment purpose   \n",
       "13            非対照    単群比較   治療  ...  treatment purpose   \n",
       "..            ...     ...  ...  ...                ...   \n",
       "238           非対照    単群比較   治療  ...  treatment purpose   \n",
       "240           非対照    単群比較   治療  ...  treatment purpose   \n",
       "242      実薬(治療)対照  並行群間比較   治療  ...  treatment purpose   \n",
       "257           非対照    単群比較   治療  ...  treatment purpose   \n",
       "261           非対照    単群比較   治療  ...  treatment purpose   \n",
       "\n",
       "                                    Inclusion Criteria  \\\n",
       "3    (1) Patients scheduled to undergo anatomical l...   \n",
       "4    Parts 1, 2, and 3 inclusion criteria: \\n\\r\\n-H...   \n",
       "9    1)\\tHistologically diagnosed with cutaneous an...   \n",
       "12   -Phase 1a (Dose Escalation) and 1b (Dose Expan...   \n",
       "13   -Male or female participants at least 18 years...   \n",
       "..                                                 ...   \n",
       "238  -Patients aged between 20 and 80 (75 for the p...   \n",
       "240  1. Patients who are 20 years old or above at t...   \n",
       "242  Patients must meet the following criteria to b...   \n",
       "257  (Phase 1)\\n\\r\\n1) Histologically confirmed mal...   \n",
       "261  Inclusion criteria \\n\\r\\nPatients meeting all ...   \n",
       "\n",
       "                                    Exclusion Criteria     Age Minimum  \\\n",
       "3    (1) Patients with a history of allergy to the ...  18age old over   \n",
       "4    Parts 1, 2, and 3 exclusion criteria:\\n\\r\\n-Ha...  18age old over   \n",
       "9    1)\\tPatients previously treated with anti-PD-1...  18age old over   \n",
       "12   -Prior therapy selectively targeting CDK4 (pri...  18age old over   \n",
       "13   -Has ongoing adverse reaction(s) from prior th...  18age old over   \n",
       "..                                                 ...             ...   \n",
       "238  -Patients who are scheduled to receive high-do...  20age old over   \n",
       "240  1. Patients with active duplicate cancer\\n\\r\\n...  20age old over   \n",
       "242  Patients with any of the following will be exc...  18age old over   \n",
       "257  (Phase 1 and 2)\\n\\r\\n1) Patients who have brai...  20age old over   \n",
       "261  Exclusion criteria\\n\\r\\nPatients meeting any o...  20age old over   \n",
       "\n",
       "         Age Maximum Gender Discontinuation Criteria  \\\n",
       "3           No limit   Both                      NaN   \n",
       "4           No limit   Both                      NaN   \n",
       "9    85age old under   Both                      NaN   \n",
       "12          No limit   Both                      NaN   \n",
       "13          No limit   Both                      NaN   \n",
       "..               ...    ...                      ...   \n",
       "238  80age old under   Both                      NaN   \n",
       "240         No limit   Both                      NaN   \n",
       "242         No limit   Both                      NaN   \n",
       "257         No limit   Both                      NaN   \n",
       "261    86age old not   Both                      NaN   \n",
       "\n",
       "                                  Keyword  \\\n",
       "3                                     NaN   \n",
       "4                                     NaN   \n",
       "9    cutaneous angiosarcoma, angiosarcoma   \n",
       "12                                    NaN   \n",
       "13                                    NaN   \n",
       "..                                    ...   \n",
       "238                                   NaN   \n",
       "240                                   NaN   \n",
       "242                                   NaN   \n",
       "257   malignamt  melanoma, advanced stage   \n",
       "261                     advanced melanoma   \n",
       "\n",
       "                                       Intervention(s) Phase  \n",
       "3    Treatment group\\n\\r\\nAdminister GRA 1mg intrav...   NaN  \n",
       "4            Drug: GSK4418959\\n\\r\\nDrug:PD-1 inhibitor   NaN  \n",
       "9    Each course is set at 21 days. Pembrolizumab 2...   NaN  \n",
       "12   -Drug: BGB-43395\\n\\r\\nPlanned doses administer...   NaN  \n",
       "13   Drug: GSK5764227\\n\\r\\nGSK5764227 will be admin...   NaN  \n",
       "..                                                 ...   ...  \n",
       "238  OPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\...   NaN  \n",
       "240  Once a day for orally\\n\\r\\n1mg/kg, 2.5mg/kg, 5...   NaN  \n",
       "242  ASP-1929 640mg/m^2 intravenous infusion by dri...   NaN  \n",
       "257  Test drug (T-hIL12) will be administered into ...   NaN  \n",
       "261  combination therapy of intracutaneous GEN0101 ...   NaN  \n",
       "\n",
       "[124 rows x 35 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.dropna(subset=['試験等のフェーズ'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "nan_rows_df = df[df['試験等のフェーズ'].isna()]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>JRCT ID</th>\n",
       "      <th>Title</th>\n",
       "      <th>Target</th>\n",
       "      <th>研究・治験の目的</th>\n",
       "      <th>試験の種類</th>\n",
       "      <th>無作為化</th>\n",
       "      <th>盲検化</th>\n",
       "      <th>対照</th>\n",
       "      <th>割付け</th>\n",
       "      <th>研究目的</th>\n",
       "      <th>...</th>\n",
       "      <th>purpose</th>\n",
       "      <th>Inclusion Criteria</th>\n",
       "      <th>Exclusion Criteria</th>\n",
       "      <th>Age Minimum</th>\n",
       "      <th>Age Maximum</th>\n",
       "      <th>Gender</th>\n",
       "      <th>Discontinuation Criteria</th>\n",
       "      <th>Keyword</th>\n",
       "      <th>Intervention(s)</th>\n",
       "      <th>Phase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>jRCT1030240513</td>\n",
       "      <td>進行がん患者に対する可聴領域外のハイレゾ自然音源が与える生体情報や癒しの変化を評価する\\n探...</td>\n",
       "      <td>がん</td>\n",
       "      <td>進行がん患者を対象に、可聴領域外のハイレゾ自然音源を介入とした音楽療法が、無音と比較して、疲...</td>\n",
       "      <td>介入研究</td>\n",
       "      <td>無作為化比較</td>\n",
       "      <td>単盲検</td>\n",
       "      <td>プラセボ対照</td>\n",
       "      <td>並行群間比較</td>\n",
       "      <td>緩和</td>\n",
       "      <td>...</td>\n",
       "      <td>supportive care</td>\n",
       "      <td>Eligible participants must meet the following ...</td>\n",
       "      <td>Exclusion criteria apply if any of the followi...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cancer,</td>\n",
       "      <td>Participants will be exposed to either sounds ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>jRCT1032240511</td>\n",
       "      <td>進行がん患者の痛みに対する交番磁界治療器の至適な治療時間の条件に関する多施設共同研究</td>\n",
       "      <td>がん患者の疼痛</td>\n",
       "      <td>交番磁界治療器を用いた自宅での疼痛治療について、進行がん患者が治療の継続が可能と考える治療時...</td>\n",
       "      <td>介入研究</td>\n",
       "      <td>単一群</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>その他</td>\n",
       "      <td>...</td>\n",
       "      <td>other</td>\n",
       "      <td>1. Age 18 years or older on the day of consent...</td>\n",
       "      <td>1. There is a skin disorder in the painful are...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Four pads of the alternating magnetic field th...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>jRCT1032240506</td>\n",
       "      <td>卵巣腫瘍手術での術中低圧換気介入による術中出血量に及ぼす影響:ランダム化比較試験</td>\n",
       "      <td>卵巣がん</td>\n",
       "      <td>卵巣悪性腫瘍手術は高侵襲な手術であり輸血率の高い手術である。一方で輸血により癌の予後が悪化す...</td>\n",
       "      <td>介入研究</td>\n",
       "      <td>無作為化比較</td>\n",
       "      <td>単盲検</td>\n",
       "      <td>実薬(治療)対照</td>\n",
       "      <td>並行群間比較</td>\n",
       "      <td>治療</td>\n",
       "      <td>...</td>\n",
       "      <td>treatment purpose</td>\n",
       "      <td>Patients undergoing ovarian cancer surgery at ...</td>\n",
       "      <td>1.Minors\\n\\r\\n2.Emergency surgery\\n\\r\\n3.Patie...</td>\n",
       "      <td>18age old over</td>\n",
       "      <td>100age old not</td>\n",
       "      <td>Female</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Low-pressure ventilation and low venous pressu...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>jRCT1042240125</td>\n",
       "      <td>Liquid Biopsyによる膵がん早期診断法の開発</td>\n",
       "      <td>膵嚢胞、慢性膵炎、家族性膵がん及び遺伝性膵がん家族歴を有する症例、糖尿病症例(新規発症・急性...</td>\n",
       "      <td>本研究では、膵がん高危険群である膵のう胞性病変等を対象にサーベイランスプログラムを立ち上げ、...</td>\n",
       "      <td>観察研究</td>\n",
       "      <td>単一群</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>非対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>診断</td>\n",
       "      <td>...</td>\n",
       "      <td>diagnostic purpose</td>\n",
       "      <td>1. Cases diagnosed as high-risk group for panc...</td>\n",
       "      <td>1. Post-Pancreatic Surgery Cases\\n\\r\\n2. Cases...</td>\n",
       "      <td>20age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>jRCT1052240186</td>\n",
       "      <td>トリモーダルプレハビリテーションが周術期の睡眠に及ぼす影響の検討:ランダム化比較試験</td>\n",
       "      <td>肺がん</td>\n",
       "      <td>術前の介入により、介入群の方が対照群に比べて入院直後の睡眠効率が良いかどうかを検討すること</td>\n",
       "      <td>介入研究</td>\n",
       "      <td>無作為化比較</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>無治療対照/標準治療対照</td>\n",
       "      <td>単群比較</td>\n",
       "      <td>予防</td>\n",
       "      <td>...</td>\n",
       "      <td>prevention purpose</td>\n",
       "      <td>1) Patients aged 20 and over \\n\\r\\n2) Lung can...</td>\n",
       "      <td>1) Patients who do not agree \\n\\r\\n2) Patients...</td>\n",
       "      <td>20age old over</td>\n",
       "      <td>No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Malignancy</td>\n",
       "      <td>Intervention for the Experimental Group:\\n\\r\\n...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>282</th>\n",
       "      <td>jRCT2080223823</td>\n",
       "      <td>固形がん患者を対象としたE7130 の臨床第1相試験</td>\n",
       "      <td>Part1:固形がん\\nPart2:頭頸部がん,尿路上皮がん</td>\n",
       "      <td>NaN</td>\n",
       "      <td>介入研究</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>&lt;p&gt;Both&lt;/p&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>investigational material(s)&lt;br&gt;\\nGeneric name ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>283</th>\n",
       "      <td>jRCT1090220266</td>\n",
       "      <td>肺がん手術患者に対する運動療法とBCAA摂取の併用効果の検討</td>\n",
       "      <td>肺がん</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>実薬(治療)対照</td>\n",
       "      <td>なし</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Age Month Week Day Hour</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intervention type:BEHAVIOUR\\n\\nName of interve...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>284</th>\n",
       "      <td>jRCT1091220254</td>\n",
       "      <td>肺動静脈分離3D-CT angiographyにおけるヨード造影剤量低減の検討</td>\n",
       "      <td>肺がん</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>単盲検</td>\n",
       "      <td>用量比較</td>\n",
       "      <td>あり</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intervention type:DRUG\\n\\nName of intervention...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>285</th>\n",
       "      <td>jRCT1090220224</td>\n",
       "      <td>体幹部神経ブロック後のレボブピバカインの血中濃度の変化</td>\n",
       "      <td>下腹部消化器がん</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>無対照</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>20Age Month Week Day Hour over</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intervention type:\\n\\nName of intervention:\\n\\...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>286</th>\n",
       "      <td>jRCT1091220221</td>\n",
       "      <td>ヨード造影剤と生理食塩水の混合溶液を用いたtest injectionによる混合割合と造影効...</td>\n",
       "      <td>肺がん</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>非盲検</td>\n",
       "      <td>無対照</td>\n",
       "      <td>なし</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Age Month Week Day Hour No limit</td>\n",
       "      <td>Both</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Intervention type:DRUG\\n\\nName of intervention...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>163 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            JRCT ID                                              Title  \\\n",
       "0    jRCT1030240513  進行がん患者に対する可聴領域外のハイレゾ自然音源が与える生体情報や癒しの変化を評価する\\n探...   \n",
       "1    jRCT1032240511         進行がん患者の痛みに対する交番磁界治療器の至適な治療時間の条件に関する多施設共同研究   \n",
       "2    jRCT1032240506           卵巣腫瘍手術での術中低圧換気介入による術中出血量に及ぼす影響:ランダム化比較試験   \n",
       "5    jRCT1042240125                        Liquid Biopsyによる膵がん早期診断法の開発   \n",
       "6    jRCT1052240186         トリモーダルプレハビリテーションが周術期の睡眠に及ぼす影響の検討:ランダム化比較試験   \n",
       "..              ...                                                ...   \n",
       "282  jRCT2080223823                         固形がん患者を対象としたE7130 の臨床第1相試験   \n",
       "283  jRCT1090220266                     肺がん手術患者に対する運動療法とBCAA摂取の併用効果の検討   \n",
       "284  jRCT1091220254            肺動静脈分離3D-CT angiographyにおけるヨード造影剤量低減の検討   \n",
       "285  jRCT1090220224                       体幹部神経ブロック後のレボブピバカインの血中濃度の変化    \n",
       "286  jRCT1091220221  ヨード造影剤と生理食塩水の混合溶液を用いたtest injectionによる混合割合と造影効...   \n",
       "\n",
       "                                                Target  \\\n",
       "0                                                   がん   \n",
       "1                                              がん患者の疼痛   \n",
       "2                                                 卵巣がん   \n",
       "5    膵嚢胞、慢性膵炎、家族性膵がん及び遺伝性膵がん家族歴を有する症例、糖尿病症例(新規発症・急性...   \n",
       "6                                                  肺がん   \n",
       "..                                                 ...   \n",
       "282                     Part1:固形がん\\nPart2:頭頸部がん,尿路上皮がん   \n",
       "283                                                肺がん   \n",
       "284                                                肺がん   \n",
       "285                                          下腹部消化器がん    \n",
       "286                                                肺がん   \n",
       "\n",
       "                                              研究・治験の目的 試験の種類    無作為化  盲検化  \\\n",
       "0    進行がん患者を対象に、可聴領域外のハイレゾ自然音源を介入とした音楽療法が、無音と比較して、疲...  介入研究  無作為化比較  単盲検   \n",
       "1    交番磁界治療器を用いた自宅での疼痛治療について、進行がん患者が治療の継続が可能と考える治療時...  介入研究     単一群  非盲検   \n",
       "2    卵巣悪性腫瘍手術は高侵襲な手術であり輸血率の高い手術である。一方で輸血により癌の予後が悪化す...  介入研究  無作為化比較  単盲検   \n",
       "5    本研究では、膵がん高危険群である膵のう胞性病変等を対象にサーベイランスプログラムを立ち上げ、...  観察研究     単一群  非盲検   \n",
       "6        術前の介入により、介入群の方が対照群に比べて入院直後の睡眠効率が良いかどうかを検討すること  介入研究  無作為化比較  非盲検   \n",
       "..                                                 ...   ...     ...  ...   \n",
       "282                                                NaN  介入研究     NaN  NaN   \n",
       "283                                                NaN   NaN     NaN  非盲検   \n",
       "284                                                NaN   NaN     NaN  単盲検   \n",
       "285                                                NaN   NaN     NaN  非盲検   \n",
       "286                                                NaN   NaN     NaN  非盲検   \n",
       "\n",
       "               対照     割付け 研究目的  ...             purpose  \\\n",
       "0          プラセボ対照  並行群間比較   緩和  ...     supportive care   \n",
       "1             非対照    単群比較  その他  ...               other   \n",
       "2        実薬(治療)対照  並行群間比較   治療  ...   treatment purpose   \n",
       "5             非対照    単群比較   診断  ...  diagnostic purpose   \n",
       "6    無治療対照/標準治療対照    単群比較   予防  ...  prevention purpose   \n",
       "..            ...     ...  ...  ...                 ...   \n",
       "282           NaN     NaN  NaN  ...                 NaN   \n",
       "283      実薬(治療)対照      なし  NaN  ...                 NaN   \n",
       "284          用量比較      あり  NaN  ...                 NaN   \n",
       "285           無対照     NaN  NaN  ...                 NaN   \n",
       "286           無対照      なし  NaN  ...                 NaN   \n",
       "\n",
       "                                    Inclusion Criteria  \\\n",
       "0    Eligible participants must meet the following ...   \n",
       "1    1. Age 18 years or older on the day of consent...   \n",
       "2    Patients undergoing ovarian cancer surgery at ...   \n",
       "5    1. Cases diagnosed as high-risk group for panc...   \n",
       "6    1) Patients aged 20 and over \\n\\r\\n2) Lung can...   \n",
       "..                                                 ...   \n",
       "282                                                NaN   \n",
       "283                                                NaN   \n",
       "284                                                NaN   \n",
       "285                                                NaN   \n",
       "286                                                NaN   \n",
       "\n",
       "                                    Exclusion Criteria  \\\n",
       "0    Exclusion criteria apply if any of the followi...   \n",
       "1    1. There is a skin disorder in the painful are...   \n",
       "2    1.Minors\\n\\r\\n2.Emergency surgery\\n\\r\\n3.Patie...   \n",
       "5    1. Post-Pancreatic Surgery Cases\\n\\r\\n2. Cases...   \n",
       "6    1) Patients who do not agree \\n\\r\\n2) Patients...   \n",
       "..                                                 ...   \n",
       "282                                                NaN   \n",
       "283                                                NaN   \n",
       "284                                                NaN   \n",
       "285                                                NaN   \n",
       "286                                                NaN   \n",
       "\n",
       "                          Age Minimum                       Age Maximum  \\\n",
       "0                      18age old over                          No limit   \n",
       "1                      18age old over                          No limit   \n",
       "2                      18age old over                    100age old not   \n",
       "5                      20age old over                          No limit   \n",
       "6                      20age old over                          No limit   \n",
       "..                                ...                               ...   \n",
       "282                               NaN                               NaN   \n",
       "283           Age Month Week Day Hour  Age Month Week Day Hour No limit   \n",
       "284  Age Month Week Day Hour No limit  Age Month Week Day Hour No limit   \n",
       "285    20Age Month Week Day Hour over  Age Month Week Day Hour No limit   \n",
       "286  Age Month Week Day Hour No limit  Age Month Week Day Hour No limit   \n",
       "\n",
       "          Gender Discontinuation Criteria     Keyword  \\\n",
       "0            NaN                      NaN     cancer,   \n",
       "1           Both                      NaN         NaN   \n",
       "2         Female                      NaN         NaN   \n",
       "5           Both                      NaN         NaN   \n",
       "6           Both                      NaN  Malignancy   \n",
       "..           ...                      ...         ...   \n",
       "282  <p>Both</p>                      NaN         NaN   \n",
       "283         Both                      NaN         NaN   \n",
       "284         Both                      NaN         NaN   \n",
       "285         Both                      NaN         NaN   \n",
       "286         Both                      NaN         NaN   \n",
       "\n",
       "                                       Intervention(s) Phase  \n",
       "0    Participants will be exposed to either sounds ...   NaN  \n",
       "1    Four pads of the alternating magnetic field th...   NaN  \n",
       "2    Low-pressure ventilation and low venous pressu...   NaN  \n",
       "5                                                  NaN   NaN  \n",
       "6    Intervention for the Experimental Group:\\n\\r\\n...   NaN  \n",
       "..                                                 ...   ...  \n",
       "282  investigational material(s)<br>\\nGeneric name ...   NaN  \n",
       "283  Intervention type:BEHAVIOUR\\n\\nName of interve...   NaN  \n",
       "284  Intervention type:DRUG\\n\\nName of intervention...   NaN  \n",
       "285  Intervention type:\\n\\nName of intervention:\\n\\...   NaN  \n",
       "286  Intervention type:DRUG\\n\\nName of intervention...   NaN  \n",
       "\n",
       "[163 rows x 35 columns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nan_rows_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "gradio",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}